Alevatrix™
Postoperative pain
IND-enablingActive
Key Facts
About Rebel Medicine
Rebel Medicine is a private, preclinical-stage biotechnology company developing novel, extended-release local anesthetics to address the opioid crisis in post-operative pain management. The company's core technology platform enables the formulation of bupivacaine into long-acting gels and solutions, with its lead asset, Alevatrix™, having completed a Pre-IND meeting. Backed by non-dilutive grant funding from the NSF and NIH, Rebel aims to establish a new standard of care in loco-regional anesthesia that minimizes or eliminates the need for systemic opioids after surgery.
View full company profileTherapeutic Areas
Other Postoperative pain Drugs
| Drug | Company | Phase |
|---|---|---|
| SBG004 | Sonoran Biosciences | Pre-clinical/Phase 1 |
| TT5 | Tafalgie Therapeutics | Phase 1 |
| LT1001 | Lumosa Therapeutics | Market |